Guess which small cap ASX stock is rocketing 45% on benchmark agreement

What is getting investors excited on Friday? Let's find out.

4DMedical Ltd (ASX: 4DX) shares are catching the eye on Friday morning.

In early trade, the small cap ASX stock is rocketing 45% higher to 64.5 cents.

A bearded man holds both arms up diagonally and points with his index fingers to the sky with a thrilled look on his face.

Image source: Getty Images

Why is this small cap ASX stock rocketing?

Investors have been fighting to get hold of the respiratory imaging technology company's shares this morning after it announced a major agreement in the United States.

According to the release, 4DMedical has signed a distribution agreement that appoints global healthcare giant Philips (NYSE: PHG) as an authorised reseller across the United States.

This follows the signing of a teaming agreement with Philips in January to establish a strategic collaboration to advance solutions to evaluate Veterans with deployment-related respiratory disease (DRRD) and other respiratory conditions as part of a broader lung screening initiative.

Management notes that this agreement establishes a transformative commercial pathway for 4DMedical's product suite in the United States by leveraging Philips' long-established and significant existing commercial partnerships.

These existing relationships are particularly strong within the Veterans Affairs (VA) and the Department of Defense (DoD), where Philips has been providing innovative solutions for over 45 years. It highlights that 50% of VA clinics currently use Philips imaging solutions.

Massive market opportunity

Management believes the opportunities within the VA are twofold.

Firstly, the two parties will work together to support the need for scalable, non-invasive lung screening in support of the PACT Act. The PACT Act represents a US$280 billion commitment over ten years, covering numerous respiratory illnesses as presumptive conditions, providing healthcare eligibility to 6 million Veterans exposed to airborne hazards while on deployment.

It notes that 4DMedical's FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS) and LDAf are currently the two leading non-invasive technologies capable of assessing DRRD.

Secondly, management believes 4DMedical's comprehensive portfolio of products is extremely well placed to provide actionable insights to frontline VA physicians treating patients with chronic lung disease. This is particularly important when considering that Veterans have three times the rates of chronic lung diseases compared to the general population. The VA annual healthcare budget is more than US$330 billion per annum.

The small cap ASX stock's CEO and founder, Andreas Fouras, commented:

The agreement with Philips sets a new benchmark in lung health and transforms our ability to deliver our technology to patients and their doctors. Together, Philips and 4DMedical will deliver lung function analyses for all lung disorders, including unexplained dyspnoea (shortness of breath), asthma, COPD, and interstitial lung disease (ILD).

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Male and female scientists analysing data on a computer.
Healthcare Shares

Why I'd buy this ASX biotechnology company over CSL

The potential for research-driven growth could be large.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Neuren Pharmaceuticals shares just hit a 12-month high. There could be more good news to come

This week's sales figures were impressive.

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

Do I still rate CSL shares as a buy after rising 120% in four months?

Let's see if it is too late to buy this biotech giant's shares.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Healthcare Shares

CSL shares push past $200: Is $250 next?

How much further can the CSL share price rally go?

Read more »

Woman holding her glasses and looking at her laptop.
Healthcare Shares

ResMed or Cochlear: Which ASX healthcare share would I buy today?

I like both businesses for the long term, but their recent financial performances have given me something to think about.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Could Telix Pharmaceuticals shares double in value over the next 12 months?

Find out if the ASX biotech stock is a buy, sell, or hold now.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

3 compelling reasons to consider buying Mesoblast shares

This company has a lot going on, plus strong revenues.

Read more »

Doctor with stethoscope typing on her computer.
Healthcare Shares

Are CSL shares a buy, hold, or sell at their 52-week high?

Investors have become much more optimistic about its future. But has the share price recovery gone too far?

Read more »